01—Abstract
Summary
Summary of the 8-K filed April 10, 2025. Cited figures are marked; the original filing is the authoritative source.
Royalty Pharma plc (Nasdaq: RPRX) filed a Form 8-K dated April 10, 2025 to report the appointment of Dr. Vlad Coric to its Board of Directors, effective April 7, 2025.
Dr. Coric will stand for election for the first time at the 2025 Annual General Meeting and Special Meeting of Shareholders, and is expected to join the Management Development and Compensation Committee after that meeting if elected. The Board has determined that he meets applicable independence standards under Nasdaq Global Select Market rules and Item 407(a) of Regulation S-K. He will receive compensation under the Company's Independent Director Compensation Policy, as described in the preliminary proxy statement filed February 13, 2025, and will enter into a standard deed of indemnity.
The filing also attaches a press release dated April 8, 2025 announcing the appointment. That release describes Dr. Coric as Chairman and CEO of Biohaven, credits him with leading Biohaven through the FDA approval and launch of Nurtec ODT, and notes that Biohaven was sold to Pfizer in May 2022 for approximately $13 billiona in total consideration. The release also states that Biohaven has completed multiple royalty transactions with Royalty Pharma.
The filing additionally includes standard legal language referencing a pending Transaction, described as subject to shareholder approval and requiring a Schedule 14A proxy statement. The filing does not describe the Transaction's terms in detail beyond its stated expected benefits.
02—Key points
Key Highlights
- Dr. Vlad Coric was appointed to the Board of Directors effective April 7, 2025, and will stand for election for the first time at the 2025 Annual General Meeting.
- The Board determined Dr. Coric is independent under Nasdaq Global Select Market standards and Item 407(a) of Regulation S-K.
- If elected, Dr. Coric is expected to join the Management Development and Compensation Committee after the Annual Meeting.
- Dr. Coric will receive compensation under the Company's Independent Director Compensation Policy and enter into a standard deed of indemnity.
- Dr. Coric previously led Biohaven, which had completed multiple royalty transactions with Royalty Pharma, according to the attached press release.
- Biohaven's sale to Pfizer in May 2022 was for approximately $13 billion in total consideration, per the press release.
- The filing references a pending Transaction, which is subject to shareholder approval and a Schedule 14A proxy statement.
03—Questions
Frequently Asked Questions
Who was appointed to Royalty Pharma's Board of Directors?
Dr. Vlad Coric was appointed to the Board effective April 7, 2025. The company announced the appointment in a press release dated April 8, 2025.
When will Dr. Coric stand for election to the Board?
He will stand for election for the first time at the Company's 2025 Annual General Meeting and Special Meeting of Shareholders.
Which committee is Dr. Coric expected to join?
If elected, he is expected to become a member of the Management Development and Compensation Committee after the Annual Meeting.
Is Dr. Coric considered independent?
Yes. The Board determined that he meets the independence standards adopted under Nasdaq Global Select Market corporate governance listing standards and Item 407(a) of Regulation S-K.
What is Dr. Coric's background?
According to the press release, he is Chairman and CEO of Biohaven, previously led its FDA approval and launch of Nurtec ODT, and has more than 20 years of experience in drug discovery and clinical development at Yale School of Medicine and Bristol-Myers Squibb.
04—Continue